SCHEMBL22684175

SCHEMBL22684175

COc1nc(Br)cc(N)c1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CASP1 P29466 1/20 0.33
AURKA O14965 1/20 0.33
TTK P33981 1/20 0.33
AURKB Q96GD4 1/20 0.33
INCENP Q9NQS7 1/20 0.33
APP P05067 1/20 0.32
CCR4 P51679 1/20 0.31
SLC2A1 P11166 1/20 0.31
RECQL P46063 1/20 0.31
PIK3CA P42336 1/20 0.30
MAPK8 P45983 1/20 0.30
MAPK9 P45984 1/20 0.30
NSD2 O96028 1/20 0.30
CASP6 P55212 1/20 0.30
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30432264 1.00 POLB (0.38) POLBL3MBTL1MAPTNPSR1CASP1
SCHEMBL25205338 0.82 POLB (0.39) POLBL3MBTL1MAPTNPSR1CASP1
SCHEMBL1514960 0.81 POLB (0.44) POLBL3MBTL1MAPTCASP1AURKA
SCHEMBL30929289 0.80 CCR4 (0.36) POLBL3MBTL1MAPTNPSR1CCR4
SCHEMBL18337885 0.80 CCR4 (0.36) POLBL3MBTL1MAPTNPSR1CCR4
SCHEMBL30622685 0.77 NCF1 (0.38) POLBMAPTCASP1AURKATTK
SCHEMBL27240208 0.74 POLB (0.44) POLBALDH1A1
SCHEMBL26639806 0.74 POLB (0.47) POLBL3MBTL1ALDH1A1
SCHEMBL29948393 0.72 IDO1 (0.36) POLBL3MBTL1MAPTCASP1AURKA
SCHEMBL156162 0.72 IDO1 (0.36) POLBL3MBTL1MAPTCASP1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740478-B1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-11-01 EP disclosed
CN-111601799-B Fused imidazole derivatives as Il-17 modulators UCB生物制药有限责任公司 2023-06-09 CN disclosed
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators UCB Biopharma SRL (BE) 2022-10-18 US disclosed
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators UCB Biopharma SRL (BE) 2021-02-25 US disclosed
EP-3740478-A1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2020-11-25 EP disclosed
CN-111601799-A Fused imidazole derivatives as Il-17 modulators UCB生物制药有限责任公司 2020-08-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators IL17A, IL2, IL23R POLB 3243/4885L3MBTL1 3057/4885MAPT 1590/4885
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators IL17A, IL2, IL23R POLB 3243/4885L3MBTL1 3057/4885MAPT 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.